Hong Kong | March 30, 2026
AI Collaboration Accelerates CNS Drug Discovery
Insilico Medicine and Tenacia Biotechnology have announced a significant expansion of their AI-driven drug discovery collaboration, strengthening their focus on central nervous system (CNS) therapeutics. Building on the success of their initial partnership launched in March 2025, the companies are now advancing a second program aimed at developing innovative small-molecule therapies with enhanced blood–brain barrier (BBB) permeability. This collaboration leverages Insilico’s proprietary Pharma.AI platform alongside Tenacia’s deep expertise in neuroscience and access to proprietary biological datasets, enabling faster identification and optimization of drug candidates. The initial program has already shown promising progress, validating the potential of generative artificial intelligence in accelerating early-stage drug discovery for complex neurological conditions.
Expanded Agreement and $94.75M Deal Potential
Under the expanded agreement, the partners will jointly develop an additional therapeutic candidate targeting challenging neurological diseases, advancing it to the preclinical candidate (PCC) stage. The deal includes a total potential value of up to US$94.75 million, with Insilico eligible for near-term payments and milestone-based incentives. The strategy emphasizes designing molecules with distinct pharmacological profiles, which may improve clinical success rates and reduce late-stage development risks.
By diversifying candidate profiles for the same biological target, the collaboration aims to generate more precise and differentiated treatment options for patients suffering from complex CNS disorders. This approach reflects a growing industry trend toward integrating AI-driven molecular design to enhance efficiency, accuracy, and scalability in drug development pipelines.
Advertisement
Strategic Impact on Neuroscience Innovation
The partnership highlights the increasing importance of AI-powered platforms in transforming pharmaceutical R&D, particularly in areas like neuroscience where traditional drug discovery has faced high failure rates. Insilico’s leadership emphasized that launching a second program within such a short timeframe demonstrates the speed, flexibility, and scalability of generative AI technologies. Meanwhile, Tenacia underscored its commitment to addressing unmet medical needs in neurological disorders, combining scientific expertise with advanced computational tools to deliver next-generation therapeutics.
This collaboration also complements Insilico’s broader expansion in CNS research, including its recent co-development efforts targeting neuroinflammatory pathways and Parkinson’s disease, further reinforcing its position as a leader in AI-driven biopharmaceutical innovation. With strong backing from investors and a focus on high-impact therapeutic areas, both companies are well-positioned to drive meaningful advancements in precision medicine for neurological diseases.
Source: Insilico Medicine, Tenacia Biotechnology press release
